Patent intelligence · US
US 12370245
ALK polypeptides and methods of use thereof
ALK polypeptides and methods of use thereof
Patent details — US 12370245
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 29, 2025
- Expiration
- Jul 24, 2045
- Applicant
- Elicio Therapeutics, Inc.
- Claims
- 9
- CPC classes
- A61K, A61K2039/55555, A61K2039/6018, A61K2039/6031
Quick answer
US 12370245 (ALK polypeptides and methods of use thereof) is held by Elicio Therapeutics, Inc.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Elicio Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K2039/55555, A61K2039/6018, A61K2039/6031, A61K2039/627, A61K31/4545
More from Elicio Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12370245?
US 12370245 (ALK polypeptides and methods of use thereof) is held by Elicio Therapeutics, Inc.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12370245?
Elicio Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12370245 expire?
Our index shows an expiration date of Jul 24, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.